CVKD

Cadrenal Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cadrenal.com
Employees(FY) 3
ISIN US1276361086

Performance

-15.33%

1W

+5.41%

1M

-48.63%

3M

-8.87%

6M

-44.45%

YTD

-71.06%

1Y

Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Advanced Technical Analysis

Technical Analysis of CVKD 2024-05-10

Overview:

In analyzing the technical indicators for CVKD stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key indicators such as moving averages, MACD, RSI, Stochastic Oscillator, Bollinger B...

See more ...

Recent News & Updates

2024-05-09 01:53
CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-08 21:00
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update(Prnewswire)
2024-04-11 04:30
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024(Prnewswire)
2024-04-08 21:00
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts(Prnewswire)
2024-03-10 21:00
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update(Prnewswire)
2024-02-25 20:00
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference(Prnewswire)
2024-02-07 20:00
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial(Prnewswire)
2024-01-30 20:00
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions(Prnewswire)
2024-01-23 20:00
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024(Prnewswire)
2024-01-03 20:00
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference(Prnewswire)
2023-12-18 20:00
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target(Prnewswire)
2023-12-11 20:00
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization(Prnewswire)
2023-11-30 03:15
Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023(Prnewswire)
2023-11-08 20:00
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update(Prnewswire)
2023-10-15 20:38
Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference(Prnewswire)
2023-10-09 04:15
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference(Prnewswire)
2023-09-04 20:00
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress(Yahoo Finance)
2023-08-29 20:00
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)(Yahoo Finance)
2023-08-28 04:15
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-09 21:00
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update(Yahoo Finance)
2023-07-31 21:00
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases(Yahoo Finance)
2023-07-23 21:00
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors(Yahoo Finance)
2023-07-14 03:02
Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules(Yahoo Finance)
2023-07-12 03:17
Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules(Yahoo Finance)
2023-06-27 18:23
The 3 Hottest IPOs to Buy Before They Soar(Yahoo Finance)
2023-05-31 21:00
Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston(Yahoo Finance)
2023-05-09 21:00
Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update(Yahoo Finance)
2023-05-09 04:30
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference(Yahoo Finance)
2023-03-29 21:00
Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update(Yahoo Finance)
2023-03-08 20:00
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population(Yahoo Finance)

Page 1 of 2

previousnext